| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | FH535 | GDSC1000 | pan-cancer | AAC | -0.0062 | 0.9 |
| mRNA | Camptothecin | GDSC1000 | pan-cancer | AAC | 0.0062 | 0.9 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | -0.007 | 0.9 |
| mRNA | KIN001-135 | GDSC1000 | pan-cancer | AAC | 0.0094 | 0.9 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | -0.0058 | 0.9 |
| mRNA | BRD-K51490254 | CTRPv2 | pan-cancer | AAC | -0.0067 | 0.9 |
| mRNA | Elesclomol | GDSC1000 | pan-cancer | AAC | 0.0059 | 0.9 |
| mRNA | hyperforin | CTRPv2 | pan-cancer | AAC | 0.0068 | 0.9 |
| mRNA | pitstop2 | CTRPv2 | pan-cancer | AAC | -0.0081 | 0.9 |
| mRNA | BRD-K34485477 | CTRPv2 | pan-cancer | AAC | 0.013 | 0.9 |